|
International Rare Brain Tumor Registry
RECRUITINGSponsored by Children's National Research Institute
Actively Recruiting
SponsorChildren's National Research Institute
Started2023-01-01
Est. completion2033-12
Eligibility
Healthy vol.Accepted
Locations4 sites
View on ClinicalTrials.gov →
NCT05697874
Summary
The objective of the International Rare Brain Tumor Registry (IRBTR) is to better understand rare brain tumors through the collection of biospecimens and matched clinical data of children, adolescents, and young adult patients diagnosed with rare brain tumors.
Eligibility
Healthy volunteers accepted
Inclusion Criteria: * Patients with a known or suspected CNS Sarcoma. * Patients with a known or suspected BCOR-altered brain tumor * Patients with a known or suspected Astroblastoma/NM-1 altered brain tumor * Patients with known or suspected histologically ambiguous/unclassifiable brain tumor * Patients with a known or suspected rare brain tumor. * Signed informed consent by patient/ parent or guardian (assent where applicable) to participate in the study. Exclusion Criteria: * The patient has an extra-CNS primary tumor. * The patient is older than 46 years of age at diagnosis. * The patient or family is not willing to participate or does not sign informed consent.
Conditions5
AstroblastomaBCOR ITD SarcomaCNS SarcomaCancerUnclassified Tumor, Malignant
Locations4 sites
California
2 sitesMarie Jaeger-Krause
San Francisco, California, 94158
District of Columbia
1 siteChildren's National Hospital
Washington D.C., District of Columbia, 20010
Ohio
1 siteBrowse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
SponsorChildren's National Research Institute
Started2023-01-01
Est. completion2033-12
Eligibility
Healthy vol.Accepted
Locations4 sites
View on ClinicalTrials.gov →
NCT05697874